<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51685">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433340</url>
  </required_header>
  <id_info>
    <org_study_id>M12-965</org_study_id>
    <secondary_id>2014-001471-31</secondary_id>
    <nct_id>NCT02433340</nct_id>
  </id_info>
  <brief_title>Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study</brief_title>
  <official_title>Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, 24-week, open-label extension (OLE) study to assess the
      safety and tolerability of ABT-122 in rheumatoid arthritis (RA) subjects who have completed
      Study M12-963 Phase 2 RCT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in American College of Rheumatology (ACR) 20 Response Rate</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>ACR criteria measures improvement in tender or swollen joint counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ACR 50 Response Rate</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>ACR criteria measures improvement in tender or swollen joint counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ACR 70 Response Rate</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>ACR criteria measures improvement in tender or swollen joint counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient's Assessment of Pain</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by Joint Evaluation, Visual Analog Scale (VAS), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT), Rheumatoid Arthritis Work Instability Scale (RA-WIS), Short Form Health Survey (SF-36)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient's Global Assessment of Disease Activity</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Health Assessment Questionnaire Disability Index</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by the Health Assessment Questionnaire (HAQ-DI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in High-Sensitivity C-Reactive Protein (hsCRP)</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by hsCRP lab test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving Low Disease Activity (LDA) per DAS 28</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Determine by disease activity score using 28 joint counts (DAS 28) [CRP].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving Clinical Remission</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Determine by DAS [CRP] and CDAI criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-F) Scale</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Using the FACIT Fatigue Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Work Instability Scale - Rheumatoid Arthritis (RA-WIS)</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Using RA-WIS Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Short Form Health Survey 36 (SF-36)</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Using the SF-36 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 70 day follow-up visit (70 days after last dose of study drug)</time_frame>
    <description>Analysis of adverse events, serious adverse events, and premature discontinuation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Physical Examination</measure>
    <time_frame>From Week 0 through 70 day follow-up visit (70 days after the last dose of study drug)</time_frame>
    <description>A symptom-directed physical exam will be performed when necessary, as per Investigator's judgement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving low disease activity (LDA) per CDAI criteria</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Determined by clinical disease activity index (CDAI) criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>All subjects (Open-label extension)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will start treatment with ABT-122</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-122</intervention_name>
    <description>Injection</description>
    <arm_group_label>All subjects (Open-label extension)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed the preceding Study M12-963 (ABT-122) RCT study and have
             not developed any discontinuation criteria, as defined in Section 5.4.1 of Study
             M12-963.

          -  If female, subject must meet one of the following criteria:

               1. Postmenopausal (defined as no menses for at least 1 year).

               2. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or
                  hysterectomy).

               3. Practicing appropriate birth control, from the time of enrollment in this study
                  until at least 150 days after the last dose of study drug. Females who have
                  undergone tubal ligation will be required to agree to use a second form of
                  contraception for the same period of time.

          -  Male who agrees to follow one of the protocol-specified pregnancy avoidance measures,
             including refraining from donating sperm, for up to 150 days post last dose of study
             drug.

          -  Subjects must voluntarily sign and date an informed consent, approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the
             initiation of any screening or study-specific procedures.

          -  Subject is judged to be in good health as determined by the Investigator based on the
             results of medical history, physical examination and laboratory profile performed.

        Exclusion Criteria:

          -  Pregnant or breastfeeding female.

          -  Ongoing infections at Day 1 (Week 0) that have NOT been successfully treated within
             14 days.

          -  Anticipated requirement or receipt of any live vaccine during study participation
             including up to 120 days after the last dose of study drug.

          -  Current enrollment in another investigational study; with the exception of Study
             M12-963, which is required.

          -  Consideration by the Investigator, for any reason, that the subject is an unsuitable
             candidate to receive ABT-122.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki Mansikka, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135738</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135739</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137989</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135753</name>
      <address>
        <city>Ostrava-Trebovice</city>
        <zip>722 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135755</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135754</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 04</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137178</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135766</name>
      <address>
        <city>Erfurt</city>
        <zip>99096</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135779</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135782</name>
      <address>
        <city>Kiskunhalas</city>
        <zip>6400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135783</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135781</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135784</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135785</name>
      <address>
        <city>Nelson</city>
        <zip>7010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135788</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137179</name>
      <address>
        <city>Bochnia</city>
        <zip>32-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135786</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135790</name>
      <address>
        <city>Grodzisk Mazowieckie</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135797</name>
      <address>
        <city>Katowice</city>
        <zip>40-748</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135793</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135792</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135789</name>
      <address>
        <city>Stalowa Wola</city>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135791</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135796</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136880</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-244</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135798</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135801</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135804</name>
      <address>
        <city>Bucharest</city>
        <zip>11143</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135805</name>
      <address>
        <city>Oradea</city>
        <zip>410028</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135803</name>
      <address>
        <city>Timisoara</city>
        <zip>300057</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 31, 2016</lastchanged_date>
  <firstreceived_date>April 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerability</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
